TAKE Solutions Limited (TAKE.NS)
INR 8.67
(2.0%)
INR 8.67
(2.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 361.37 Million INR | 1.38% |
| 2022 | 356.45 Million INR | -32.79% |
| 2021 | 530.4 Million INR | -89.75% |
| 2020 | 5.17 Billion INR | -9.87% |
| 2019 | 5.73 Billion INR | 32.92% |
| 2018 | 4.31 Billion INR | 4677.99% |
| 2017 | 90.37 Million INR | -92.85% |
| 2016 | 1.26 Billion INR | -33.3% |
| 2015 | 1.89 Billion INR | 444.25% |
| 2014 | 348.08 Million INR | -73.06% |
| 2013 | 1.29 Billion INR | 38.35% |
| 2012 | 934.05 Million INR | -9.42% |
| 2011 | 1.03 Billion INR | -25.24% |
| 2010 | 1.37 Billion INR | 1142.0% |
| 2009 | -132.36 Million INR | 55.63% |
| 2008 | -298.29 Million INR | 60.81% |
| 2007 | -761.16 Million INR | -532.76% |
| 2006 | 175.88 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 420.93 Million INR | 291.24% |
| 2023 Q1 | 107.59 Million INR | -69.82% |
| 2023 FY | 361.37 Million INR | 1.38% |
| 2023 Q4 | 361.37 Million INR | 3067.13% |
| 2023 Q3 | 11.41 Million INR | -97.29% |
| 2022 Q2 | 215.57 Million INR | -26.91% |
| 2022 Q3 | 310 Million INR | 43.81% |
| 2022 Q4 | 356.45 Million INR | 14.98% |
| 2022 Q1 | 294.95 Million INR | -44.39% |
| 2022 FY | 356.45 Million INR | -32.79% |
| 2021 Q2 | 4.47 Billion INR | 1045.0% |
| 2021 Q4 | 530.4 Million INR | 61.46% |
| 2021 FY | 530.4 Million INR | -89.75% |
| 2021 Q1 | 390.45 Million INR | -92.45% |
| 2021 Q3 | 328.51 Million INR | -92.65% |
| 2020 Q1 | 1.91 Billion INR | -66.7% |
| 2020 Q4 | 5.17 Billion INR | 221.69% |
| 2020 Q2 | 4.83 Billion INR | 152.85% |
| 2020 FY | 5.17 Billion INR | -9.87% |
| 2020 Q3 | 1.6 Billion INR | -66.73% |
| 2019 Q1 | 2.5 Billion INR | -41.99% |
| 2019 Q2 | 4.87 Billion INR | 94.45% |
| 2019 Q3 | 2.58 Billion INR | -46.84% |
| 2019 Q4 | 5.73 Billion INR | 121.67% |
| 2019 FY | 5.73 Billion INR | 32.92% |
| 2018 Q2 | 158.15 Million INR | -96.43% |
| 2018 FY | 4.31 Billion INR | 4677.99% |
| 2018 Q4 | 4.31 Billion INR | -32.23% |
| 2018 Q3 | 6.37 Billion INR | 3928.32% |
| 2018 Q1 | 4.42 Billion INR | 4800.63% |
| 2017 Q3 | 2.89 Billion INR | 78.05% |
| 2017 Q2 | 1.62 Billion INR | 42.52% |
| 2017 FY | 90.37 Million INR | -92.85% |
| 2017 Q4 | 90.37 Million INR | -96.88% |
| 2017 Q1 | 1.13 Billion INR | -9.79% |
| 2016 Q3 | 1.76 Billion INR | 237.93% |
| 2016 Q4 | 1.26 Billion INR | -28.57% |
| 2016 Q2 | 523.49 Million INR | -59.73% |
| 2016 Q1 | 1.29 Billion INR | -31.38% |
| 2016 FY | 1.26 Billion INR | -33.3% |
| 2015 FY | 1.89 Billion INR | 444.25% |
| 2015 Q4 | 1.89 Billion INR | 33.95% |
| 2015 Q1 | 1.25 Billion INR | 261.09% |
| 2015 Q2 | 705.93 Million INR | -43.83% |
| 2015 Q3 | 1.41 Billion INR | 100.34% |
| 2014 Q2 | 758.17 Million INR | -40.5% |
| 2014 FY | 348.08 Million INR | -73.06% |
| 2014 Q4 | 348.08 Million INR | -72.99% |
| 2014 Q3 | 1.28 Billion INR | 69.95% |
| 2014 Q1 | 1.27 Billion INR | -1.39% |
| 2013 Q3 | 1.17 Billion INR | 9.97% |
| 2013 FY | 1.29 Billion INR | 38.35% |
| 2013 Q1 | 1.26 Billion INR | 35.15% |
| 2013 Q2 | 1.06 Billion INR | -15.47% |
| 2013 Q4 | 1.29 Billion INR | 10.13% |
| 2012 FY | 934.05 Million INR | -9.42% |
| 2012 Q4 | 934.05 Million INR | -22.26% |
| 2012 Q3 | 1.2 Billion INR | -0.55% |
| 2012 Q2 | 1.2 Billion INR | 0.0% |
| 2011 FY | 1.03 Billion INR | -25.24% |
| 2011 Q4 | 1.03 Billion INR | 0.0% |
| 2010 FY | 1.37 Billion INR | 1142.0% |
| 2009 FY | -132.36 Million INR | 55.63% |
| 2008 FY | -298.29 Million INR | 60.81% |
| 2007 FY | -761.16 Million INR | -532.76% |
| 2006 FY | 175.88 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Biocon Limited | 140.18 Billion INR | 99.742% |
| Blue Jet Healthcare Limited | -830.93 Million INR | 143.49% |
| Concord Biotech Limited | -54.04 Million INR | 768.646% |
| Dishman Carbogen Amcis Limited | 18.99 Billion INR | 98.097% |
| Jubilant Ingrevia Limited | 6.6 Billion INR | 94.53% |
| Lyka Labs Limited | 527.01 Million INR | 31.431% |
| Panacea Biotec Limited | -1.18 Billion INR | 130.498% |
| Piramal Pharma Limited | 42.27 Billion INR | 99.145% |
| SMS Lifesciences India Limited | 992.31 Million INR | 63.583% |
| Supriya Lifescience Limited | -694.68 Million INR | 152.02% |
| Syngene International Limited | -83 Million INR | 535.386% |
| Zota Health Care Limited | 942.79 Million INR | 61.671% |